There is only one Cardiolite
* Please complete the required fields below
* Salutation
* First Name * Last Name
* Professional Degree
* Specialty/Subspecialty
* Facility
* Address
* City
* State
* ZIP
* Telephone
Fax
* E-mail
Do you wish to be added to our mailing list to receive additional information about Cardiolite®?

How We'll Use This Information: Lantheus Medical Imaging may collect data from you that you provide to us voluntarily, such as your name, postal address, e-mail address, telephone number and other personal information, such as your education level, professional affiliation, marital status, or personal medical information. If you provide us with these data, you agree that we may contact you to provide you with information we believe may be of interest to you.

Your information may be provided to other parties that Lantheus Medical Imaging is working with in order to help develop programs and provide services that may be of interest to you or for processing, mailing, and/or Internet-based delivery purposes within authorized Lantheus Medical Imaging personnel in other countries. At all times, personal data are treated confidentially.

If at any time you do not wish us to contact you or if you have any questions concerning our privacy practices, please feel free to contact us at bi.webadmin@lantheus.com.

 

INDICATIONS AND USAGE FOR CARDIOLITE®:
Myocardial Imaging:  Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), is a myocardial perfusion agent that is indicated for detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects), in evaluating myocardial function and developing information for use in patient management decisions.  Cardiolite® evaluation of myocardial ischemia can be accomplished with rest and cardiovascular stress techniques (e.g. exercise or pharmacologic stress in accordance with the pharmacologic stress agent’s labeling).

CONTRAINDICATIONS:
None known.

IMPORTANT SAFETY INFORMATION: 
Cardiolite® has been rarely associated with acute severe allergic and anaphylactic events of angioedema and generalized urticaria.  In some patients the allergic symptoms developed on the second injection during Cardiolite® imaging.  The most frequently reported adverse events include headache, chest pain/angina, ST segment changes on ECG, nausea, and abnormal taste and smell.

Infrequently, death has occurred 4 to 24 hours after Tc99m Sestamibi use and is usually associated with exercise stress testing (See Section 5.2). Pharmacologic induction of cardiovascular stress may be associated with serious adverse events such as myocardial infarction, arrhythmia, hypotension, bronchoconstriction and cerebrovascular events.

WARNINGS AND PRECAUTIONS:
In studying patients in whom cardiac disease is known or suspected, care should be taken to assure continuous monitoring and treatment in accordance with safe, accepted clinical procedure.

Caution should be exercised and emergency equipment should be available when administering Cardiolite®.

Before administering Cardiolite® patients should be asked about the possibility of allergic reactions to either Cardiolite® or Miraluma®. Miraluma® is an identical compound used in breast imaging.

The contents of the vial are intended only for use in the preparation of Technetium Tc99m Sestamibi and are not to be administered directly to the patient without first undergoing the preparative procedure.

Please see full Prescribing Information: Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection)

 

Scroll up to site navigation

 

Lantheus Medical Imaging

This site is intended for U.S. Residents.
Cardiolite®, Lantheus Medical Imaging and the corporate logo are
registered trademarks of Lantheus Medical Imaging, Inc.
Use of the information on this site is subject to the terms of our Legal Notice and Privacy Policy.
© 2020 Lantheus Medical Imaging, Inc. All Rights Reserved.